

FDA Science Board Advisory Committee Meeting
December 3, 2007
Hilton Washington DC North/Gaithersburg, Gaithersburg, Maryland 20879

Draft Agenda

- 8:00 a.m. Introductions**
Kenneth I. Shine, MD, Chair
- 8:15 a.m. Commissioner's Report**
Andrew von Eschenbach, MD, Commissioner of Food and Drugs
- 8:45 a.m. Report to the Science Board**
Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer
- Critical Path Update
- 9:15 a.m. Q&A and Discussion
Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer
- 9:30 a.m. Update from the FDA on the Science Board Subcommittee Review of the National Antimicrobial Resistance Monitoring System (NARMS) Program Review**
Stephen Sundlof, DVM, PhD, Director, Center for Veterinary Medicine
- 10:00 a.m. BREAK**
- 10:15 a.m. Update on Drug Safety**
Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer
Acting Director, Center for Drug Evaluation and Research
- 10:45 a.m. Q&A and Discussion
Janet Woodcock, MD, Acting Director, Center for Drug Evaluation and Research
- 11:00 a.m. Update on Activities related to Melamine**
Norris Alderson, PhD, Associate Commissioner for Science
- 11:30 a.m. Lunch**
- 12:30 p.m. Report of the Subcommittee on Science and Technology**
Gail Cassell, PhD, D.Sc. (hon), Subcommittee Chair
- Overview of Process, Findings, and Recommendations G. Cassell
- Scientific Gaps: Capability and Capacity
- Food Safety: A State of Crisis C. Woteki
 - Genomics: Impact, Current and Future Challenges,
and Opportunities T. Caskey
 - Emerging Science: Preparedness or Catch-Up G. Fitzgerald
- Information Infrastructure: the Weakest but Most Critical Link D. Nordenberg
- Increasing Responsibilities and Resource Challenges P. Hutt

RecommendationsTBA

Summary G. Cassell

2:00 p.m. Science Board Q&A and Discussion

4:00 p.m. BREAK

4:15 p.m. Open Public Hearing

5:15 p.m. Comments from the Science Board Chair
Kenneth I. Shine, MD, Chair

5:30 p.m. Adjourn